Join to View Full Profile
80 Doctors DrSte 1Hendersonville, NC 28792
Phone+1 828-654-0073
Fax+1 828-681-5036
Are you Dr. Jackson?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Don Jackson Jr., MD is an oncologist in Hendersonville, North Carolina. He is currently licensed to practice medicine in North Carolina.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1977 - 1978
Wake Forest University Baptist Medical CenterFellowship, Hematology and Medical Oncology, 1975 - 1977- Wake Forest University Baptist Medical CenterResidency, Internal Medicine, 1973 - 1975
Carilion Clinic-Virginia Tech Carilion School of MedicineInternship, Transitional Year, 1972 - 1973
University of Virginia School of MedicineClass of 1972
Certifications & Licensure
NC State Medical License 1978 - 2023
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- DOSE‐RELATED PHARMACOLOGIC EFFECTS OF HIGH DOSE ARA‐C AND ITS USE IN COMBINATION WITH ASPARAGINASE FOR THE TREATMENT OF PATIENTS WITH ACUTE NON‐LYHPHOCYTIC LEUKEMIA*Robert L. Capizzi, Bayard L. Powell, M. Robert Cooper, James P. Rathmell, J. Courtland White
Scandinavian Journal of Haematology. Supplementum. 2009-04-24 - 256 citationsPhase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer : final report of Intergroup 0089Daniel G. Haller, Paul J. Catalano, John S. Macdonald, Mark Allen O'Rourke, Michael S. Frontiera
Journal of Clinical Oncology. 2005-12-01 - 35 citationsPhase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.William R. Berry, James W. Hathorn, Shaker R. Dakhil, David M. Loesch, Don V. Jackson
Clinical Prostate Cancer. 2004-09-01
Press Mentions
Helping Drug Users Survive, Not Abstain: ‘Harm Reduction’ Gains Federal SupportJune 27th, 2021
